AIVITA Biomedical
18301 Von Karman Avenue
Suite 130
Irvine
California
92612
United States
Tel: 949-872-2555
Website: http://aivitabiomedical.com/
About AIVITA Biomedical
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its products and therapeutic pipeline.
YEAR FOUNDED:
2016
LEADERSHIP:
CEO: Dr. Hans S. Keirstead Ph.D.
CMO: Robert O. Dillman, M.D.
CSO: Gabriel Nistor, M.D.
TECHNOLOGY:
Please click here for AIVITA's technology.
PRODUCTS:
Please click here for AIVITA's products.
99 articles about AIVITA Biomedical
-
AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
4/11/2024
AIVITA Biomedical, Inc. today announced that chief executive officer Hans Keirstead , Ph.D. and chief medical officer Robert Dillman , M.D. will speak and participate in a keynote panel at the Festival of Biologics USA , taking place April 15-19 in San Diego, California.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress
4/2/2024
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that chief executive officer Hans S. Keirstead, Ph.D. will participate in a keynote panel at the World Vaccine Congress taking place April 1-4 in Washington, D.C.
-
AIVITA Biomedical Strengthens Board of Directors with Appointment of Ex-Biogen CEO Michel Vounatsos
2/27/2024
AIVITA Biomedical, Inc. today announced the appointment of distinguished healthcare executive Michel Vounatsos to its board of directors.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Present at Biotech Showcase 2024
1/5/2024
AIVITA Biomedical, Inc. today announced that chief executive officer Hans S. Keirstead, Ph.D. will present at Biotech Showcase 2024, taking place January 8-10 in San Francisco, California.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Moderate Keynote Panel of Pharma Industry Leaders at World Vaccine Congress EU
10/13/2023
AIVITA Biomedical, Inc. announced that chief executive officer Hans S. Keirstead, Ph.D. will moderate a keynote panel and deliver a talk at the World Vaccine Congress Europe, taking place October 16-19 in Barcelona, Spain.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Participate in Keynote Panel and Deliver Talk at Festival of Biologics Europe
10/9/2023
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief executive officer Hans S. Keirstead, Ph.D. will participate in a keynote panel and deliver a talk at the Festival of Biologics Europe, taking place October 10-12 in Basel, Switzerland.
-
AIVITA Biomedical Announces Case Report Suggesting Positive Collateral Benefits in Systemic Lupus Erythematosus Achieved Through the Use of Its Dendritic Cell Vaccine Kit
9/21/2023
AIVITA Biomedical, Inc. announced the publication of a case report and literature review by distribution partners commercially deploying AIVITA's Vaccine Kit, describing collateral benefits in a patient with systemic lupus erythematosus following vaccination using AIVITA's anti-SARS-CoV-2 vaccine kit.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Advanced Therapies Europe
9/5/2023
AIVITA Biomedical, Inc. today announced that chief executive officer Hans S. Keirstead, Ph.D. will participate in a keynote panel at Advanced Therapies Europe, taking place September 5-7 in Estoril, Portugal.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote on AI in Healthcare at McKenna Institute Digital Innovation Summit
6/12/2023
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that chairman and CEO Dr. Hans Keirstead will deliver a keynote at the Digital Innovation Summit, taking place June 12-13 in St. Andrews, New Brunswick, Canada.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Present at World Vaccine Congress
4/4/2023
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief executive officer Hans S. Keirstead, Ph.D. will chair a keynote panel and talk at the World Vaccine Congress taking place April 3-6 in Washington, D.C.
-
AIVITA Biomedical Chief Medical Officer Dr. Robert Dillman to Deliver Keynote at World Immunotherapy Congress
3/16/2023
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that Chief Medical Officer Dr. Robert O. Dillman will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place Mar 20-22 in San Diego, California.
-
AIVITA Biomedical CEO Dr. Hans Keirstead Joins Human Immunome Project Board of Directors
1/9/2023
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that CEO Dr. Hans Keirstead has joined the board of the esteemed Human Immunome Project.
-
TAE Life Sciences and AIVITA Biomedical Announce Strategic Partnership to Advance Development of Target Boron Drugs for Glioblastoma
1/4/2023
TAE Life Sciences and AIVITA Biomedical Announce Strategic Partnership to Advance Development of Target Boron Drugs for Glioblastoma.
-
AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy Congress
11/29/2022
AIVITA Biomedical, Inc. announced that chief medical officer Robert O. Dillman, M.D., will chair and deliver the opening remarks for the Cancer Immunotherapy track at World Vaccine and Immunotherapy Congress West Coast, taking place Nov 28 – Dec 1 in San Diego, California.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at World Immunotherapy Congress Europe
11/1/2022
AIVITA Biomedical, Inc. announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress Europe, a submeeting of the Festival of Biologics Europe taking place Nov 2-4 in Basel, Switzerland.
-
AIVITA Biomedical CMO Dr. Robert Dillman to Deliver Keynote at Vaccines Summit 2022
10/12/2022
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief medical officer Dr. Robert O. Dillman will deliver a keynote at the second annual Vaccines Summit 2022 meeting.
-
AIVITA Biomedical Announces Publication Detailing 50% Enhanced Survival in Phase 2 GBM Study
10/4/2022
AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma study which demonstrates enhanced progression-free survival.
-
AIVITA Biomedical CEO Dr. Hans Keirstead Wins Innovator of the Year Award
9/14/2022
AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, announced that chairman and CEO Hans Keirstead, Ph.D., has received the Orange County Business Journal's 2022 Innovator of the Year Award.
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote Address at United Nations 'AI for Good' Meeting
9/13/2022
AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, announced that chairman and CEO Hans Keirstead, Ph.D., will deliver a keynote address at AI for Good, a program dedicated to achieving the United Nations Sustainable Development Goals through practical AI applications.
-
AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate
8/29/2022
AIVITA Biomedical, Inc. today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel.